[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pd-1-inhibitors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pd-1-inhibitors":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,71,98,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100618859","electro-acupuncture-in-lung-cancer--ealer-study-100618859",false,"NCT07337096","Electro-Acupuncture in Lung cancER : EALER Study","Electro-acupuncture Plus PD-1 Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer: A Randomized Trial","Inclusion Criteria:\n\n1. Pathologically confirmed NSCLC, with AJCC lung cancer TNM stage IV.\n2. Tumor proportion score for PD-L1 \\\u003C 50%.\n3. Lacks targetable gene mutations (including but not limited to EGFR mutations or ALK fusions).\n4. No prior systemic therapy for advanced NSCLC (including chemotherapy, targeted therapy, or immunotherapy). Patients planned to receive first-line (induction) treatment with ICIs plus chemotherapy are eligible. Patients who have received prior neoadjuvant or adjuvant therapy, or definitive chemoradiotherapy, may be enrolled if provided that disease progression occurred more than 6 months after the completion of the last treatment.\n5. ECOG performance status score of 0-2.\n6. Age ≥ 18 years.\n7. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n8. Adequate organ function (hematology: ANC ≥ 1500\u002FmcL, PLT ≥ 100,000\u002FmcL, Hb ≥ 9.0 g\u002FdL or ≥ 5.6 mmol\u002FL; renal function: estimated creatinine clearance ≥ 50 mL\u002Fmin; hepatic function: serum total bilirubin ≤ 1.5 × ULN or total bilirubin \\> 1.5 × ULN with direct bilirubin ≤ ULN, AST and ALT ≤ 2.5 × ULN ≤ 5 × ULN for patients with liver metastases).\n9. Voluntary participation in the study, signed informed consent form, good compliance, and cooperation with follow-up.\n\nExclusion Criteria:\n\n1. Inability to complete baseline assessments.\n2. Pregnant or lactating women, and those with psychiatric, intellectual, or language disorders.\n3. Patients with autoimmune diseases or hematologic disorders requiring long-term use of hormones or immunosuppressants.\n4. Presence of concurrent primary malignant tumors at other sites.\n5. Participation in another investigational drug or device clinical trial within 30 days prior to the planned initiation of study treatment.\n6. Known seropositivity for human immunodeficiency virus (HIV), other congenital or acquired immunodeficiencies, or history of organ or stem cell transplantation (including autologous bone marrow or peripheral blood stem cell transplantation).\n7. Loss of self-care capacity, or any medical, psychological, or ethical condition that, in the investigator's judgment, could interfere with the patient's ability to complete the study.\n8. Active skin infection, ulceration, or lesion at acupuncture point sites that would preclude safe administration of treatment.\n9. Implanted cardiac pacemaker or other active implantable electronic medical device.\n10. Severe needle phobia that would prevent acceptance of needling procedures required by the study protocol.\n11. Receipt of any acupuncture or related needle-based therapy within 6 weeks prior to enrollment.\n12. Active pneumonitis, or radiation pneumonitis requiring treatment with systemic corticosteroids.\n13. Active infection requiring antimicrobial therapy (antibacterial, antifungal, or antiviral agents) according to clinical guidelines at the time of screening. Enrollment may be reconsidered after the infection has been adequately controlled.\n14. Active tuberculosis infection, or any severe or uncontrolled systemic illness, including but not limited to clinically significant neurological conditions (e.g., uncontrolled seizures, dementia), unstable or decompensated respiratory, cardiac, hepatic, or renal disease.","ALL","18 Years",{"count":19,"type":20},424,"ESTIMATED","INTERVENTIONAL",[23],"NA","This multicentre, randomized controlled trial evaluates the effect and safety of acupuncture combing with PD-1 inhibitors plus chemotherapy in NSCLC. Participants will be randomly assigned to undergo either acupuncture or sham acupuncture concurrent with the initial four-six cycles of chemotherapy combined with PD-1 inhibitors.",[26,27,28],"Non Small Cell Lung Cancer","Accupuncture","PD-1 Inhibitors","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-01-15",{"date":37,"type":20},"2028-12",{"name":39,"class":40},"Guangzhou University of Traditional Chinese Medicine","OTHER",3,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100620547","mechanism-of-enhanced-efficacy-of-ivonescimab-in-neoadjuvant-therapy-for-non-small-cell-lung-cancer-100620547","NCT07359040","Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","Inclusion Criteria:\n\nPatients with non-small cell lung cancer (Stage IB-IIIB) who require radical surgery following neoadjuvant therapy.\n\nExclusion Criteria:\n\n1. Histology of other malignant tumors, including concurrent malignant tumors of other organ systems;\n2. Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC);\n3. Pregnancy or lactation;\n4. Insufficient sample quality;\n5. Severe organ dysfunction (e.g. cardiac or renal insufficiency);\n6. Other judgments by the Investigator that the patient should not participate in the study.",{"count":50,"type":20},80,"5 Years","OBSERVATIONAL","This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1\u002FVEGF bispecific antibody, with those of conventional PD-1 inhibitors. Beyond evaluating its direct therapeutic benefits, this research also seeks to elucidate the potential mechanisms underlying the enhanced efficacy of Ivonescimab. Additionally, the study will conduct secondary exploratory analyses, including the identification and validation of predictive and prognostic biomarkers, as well as multi-omics profiling to investigate the molecular mechanisms of action. Collectively, these efforts aim to provide comprehensive experimental data to support the rational clinical application of Ivonescimab and the development of precision medicine strategies for NSCLC.",[55,56,28,57],"Non-Small Cell Lung Cancer","Neoadjuvant Therapy","Immunotherapy",[59,60,55],"Neoajuvant therapy","Ivonescimab","2026-06-02",{"date":63,"type":33},"2026-06-03",{"date":65,"type":33},"2025-07-01",{"date":67,"type":20},"2027-10-30",{"name":69,"class":40},"Peking University People's Hospital",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":70},"100611367","electroacupuncture-combined-with-pd-1-inhibitor-for-ecog2-advanced-nsclc-100611367","NCT07239661","Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC","The Clinical Efficacy of Electroacupuncture Combined With PD-1 Inhibitor in the Treatment of ECOG2 Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients diagnosed with stage ⅢB-Ⅳ non-small cell lung cancer (NSCLC) confirmed by pathological or cytological examination;\n* Patients with negative driver gene mutations, excluding those harboring EGFR mutations, ALK rearrangements, or other common driver gene alterations as determined by genetic testing or other molecular biological methods;\n* An Eastern Cooperative Oncology Group (ECOG) performance status score of 2;\n* A programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 1%;\n* An expected survival time of more than 3 months, as assessed by the clinician based on the patient's overall condition, tumor progression, and response to treatment;\n* Patients with good treatment compliance who provided written informed consent, confirming their understanding of and willingness to undergo treatment and follow-up according to the study protocol.\n\nExclusion Criteria:\n\n* Patients with a history or concurrent diagnosis of other malignant tumors within the past five years;\n* Patients with severe organ impairment or serious comorbidities, such as cardiac dysfunction (New York Heart Association \\[NYHA\\] class Ⅲ-Ⅳ), hepatic or renal insufficiency, as determined by standard clinical examinations including liver and kidney function tests and electrocardiography;\n* Patients with untreated central nervous system (CNS) metastases were excluded; eligible patients were required to have stable disease confirmed by imaging after receiving at least one systemic or surgical treatment;\n* Patients with psychiatric disorders, including schizophrenia or bipolar disorder, particularly those requiring pharmacologic treatment;\n* Patients with a history of multiple drug allergies, an allergic predisposition, or a history of severe allergic reactions such as anaphylactic shock or allergic rash;\n* Subjects with active autoimmune or infectious diseases, including but not limited to chronic viral hepatitis, active pulmonary tuberculosis, or other infections or autoimmune disorders deemed by clinicians to potentially affect the study;\n* Female patients who were pregnant or lactating.",{"count":79,"type":20},120,[23],"The aim of this study was to systematically evaluate the clinical efficacy and safety of electroacupuncture (EA) combined with PD-1 inhibitors in patients with advanced non-small cell lung cancer (NSCLC) who have an ECOG performance status of 2 through a multicenter, randomized, sham-controlled clinical trial. The core scientific question addressed in this study was whether EA combined with standard immunotherapy could further improve progression-free survival (PFS), immune function, and quality of life in these patients. Patients meeting the inclusion criteria were randomly assigned in a 1:1 ratio to receive EA plus a PD-1 inhibitor (trial group) or sham EA plus a PD-1 inhibitor (control group) through a computerized randomization system. PD-1 inhibitors were administered every 21 days for four to six cycles, followed by maintenance therapy according to each patient's condition. EA intervention was initiated on the first day of each immunotherapy cycle and administered once daily for five sessions per cycle, continuing for four to six cycles. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), overall survival (OS), first-line treatment completion rate, quality of life as assessed by the EORTC QLQ-C30 scale, traditional Chinese medicine (TCM) syndrome score, immune function index, and incidence of adverse events according to CTCAE 5.0 criteria. In addition, peripheral blood was collected from patients at baseline for non-coding RNA sequencing, and differentially expressed genes were identified through bioinformatics analysis to determine potential molecular biomarkers associated with the synergistic effects of EA, thereby providing a basis for accurately identifying patients likely to benefit from EA therapy.",[55,83,28,84],"Electroacupuncture","ECOG PS 2 Points",[86,57,87,55,88],"electroacupuncture","immune checkpoint inhibitor","ECOG PS 2 points","2025-11-16",{"date":91,"type":33},"2025-11-20",{"date":93,"type":20},"2025-11-30",{"date":95,"type":20},"2027-12-31",{"name":97,"class":40},"Kong Fanming",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":70},"100599577","electroacupuncture-combined-with-pd-1-inhibitor-for-elderly-patients-with-advanced-nsclc-100599577","NCT07086300","Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC","Clinical Study of Electroacupuncture Combined With PD-1 Inhibitor Treatment for Elderly Patients With Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients with stage IIIB-IV non-small cell lung cancer (NSCLC) confirmed by histopathological or cytological diagnosis.\n* Patients with negative driver gene mutations, as determined by genetic testing or other molecular biological methods, to exclude common driver mutations such as EGFR mutations and ALK rearrangements.\n* Patients aged ≥65 years, with consideration for the patients' overall physical condition. Additional assessments will be conducted if there are comorbidities or other factors that may affect their physical status.\n* PD-L1 tumor proportion score (TPS) ≥1%.\n* Estimated survival time \\>3 months, as determined by clinical evaluation based on the patient's overall condition, tumor progression, and response to treatment.\n* ECOG performance status score of 0-2.\n* Patients with good treatment compliance, who are willing to sign an informed consent form, indicating their understanding and agreement to adhere to the study protocol for treatment and follow-up.\n\nExclusion Criteria:\n\n* Patients with a history of or concurrent other malignancies within the past 5 years.\n* Patients with severe organ dysfunction or other serious comorbidities, such as heart failure (NYHA Class III-IV), hepatic or renal insufficiency, as assessed by routine examinations including liver function tests, renal function tests, and electrocardiograms.\n* Patients with untreated central nervous system metastases. Only those who have undergone at least one course of systemic or surgical treatment and have been confirmed to have stable disease by imaging studies will be included.\n* Patients with psychiatric disorders, including a history of severe mental illnesses (e.g., schizophrenia, bipolar disorder) that require pharmacological treatment for control.\n* Patients with a history of multiple drug allergies or an allergic constitution, particularly those who have experienced severe allergic reactions such as anaphylactic shock or allergic rashes.\n* Patients with active autoimmune diseases or infectious diseases, including but not limited to active or chronic viral hepatitis, active pulmonary tuberculosis, or other infectious or autoimmune conditions deemed by the clinical investigator to potentially affect the study.\n* Patients who are pregnant or breastfeeding.","65 Years","100 Years",{"count":79,"type":20},[23],"The goal of this clinical trial is to elucidate the clinical efficacy and safety of electroacupuncture combined with PD-1 inhibitor therapy in elderly patients with advanced non-small cell lung cancer (NSCLC) through a multicenter, randomized controlled clinical trial. The main question it aims to answer is: the combination of electroacupuncture and PD-1 inhibitor therapy has demonstrated significant improvements in both clinical efficacy and safety profiles among elderly patients with advanced NSCLC. Researchers will compare a sham electroacupuncture group combined with PD-1 inhibitor therapy (serving as the control group) to see if the intervention group exhibits superior therapeutic efficacy and safety outcomes. Participants will be randomly assigned to one of two groups: an electroacupuncture combined with an immune checkpoint inhibitor group, or a sham electroacupuncture combined with an immune checkpoint inhibitor group. The immune checkpoint inhibitor will be administered on a 21-day cycle, with a total of 4 to 6 treatment cycles, followed by the option for maintenance therapy. Electroacupuncture treatment will commence on the same day as the initiation of the immune checkpoint inhibitor cycle, administered once daily for a total of five sessions per cycle, with 4 to 6 cycles in total. The primary outcome measure is progression-free survival (PFS). Secondary outcomes include objective response rate (ORR), quality of life, immune function, traditional Chinese medicine syndrome scores for lung cancer, and safety parameters. This study aims to establish the efficacy and safety of electroacupuncture combined with PD-1 inhibitors in elderly patients with advanced NSCLC. Additionally, peripheral non-coding RNA will be collected at baseline to analyze differentially expressed genes, thereby identifying molecular predictive biomarkers for patients who may benefit most from this combined treatment approach.",[111,55,28,83],"Elderly Patients (>65 Years)",[86,113,114,57,87],"Elderly patients","non-small cell lung cancer","2025-07-18",{"date":117,"type":33},"2025-07-25",{"date":119,"type":33},"2025-07-08",{"date":121,"type":20},"2028-12-31",{"name":97,"class":40},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":148,"locationsCount":70},"100570546","combination-of-sfrt-pd-l1-inhibitor-and-anti-vegf-in-advanced-hepatocellular-carcinoma-100570546","NCT06708650","Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma","A Single-arm, Single-center, Open-label Study to Evaluate the Efficacy and Safety of SFRT Combined With PD-1 Inhibitors and Anti-VEGFR in Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age: 18-75 years old;\n2. Eastern Cooperative Oncology Group (ECOG) -Performance Status(PS):0-1 points；\n3. Patient clinically or pathologically diagnosed with hepatocellular carcinoma；\n4. Advanced hepatocellular carcinoma that is inoperable\n5. Expected survival period≥3 months;\n6. Liver function grade Child-Pugh A or better grade B (7 points);\n\nExclusion Criteria:\n\n1. Prior invasive malignancy unless disease-free for a minimum of 2 years\n2. Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields\n3. Prior selective internal radiotherapy\u002Fablation, at any time\n4. Untreated active hepatitis B or hepatitis C\n5. Moderate to severe or intractable ascites\n6. Untreated or incompletely treated esophageal or gastric varices\n7. Severe, active co-morbidity, defined as follows:\n\n   Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months prior to registration Myocardial infarction within the last 6 months prior to study entry Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry A bleeding episode within 6 months prior to study entry due to any cause. Thrombolytic therapy within 28 days prior to study entry. Known bleeding or clotting disorder. Uncontrolled psychotic disorder\n8. Pregnancy or women of childbearing potential and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception\n9. Prior solid organ transplantation.\n10. Immunodeficiency diseases (including HIV) or autoimmune diseases require systemic immunosuppressive therapy (prednisone dosage\\>10mg per day)\n11. Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation.","75 Years",{"count":132,"type":20},50,[23],"PD-1 inhibitor plus anti-VEGFR has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Despite an improved objective response rate (ORR) of around 30%, the majority of patients face HCC progression and liver failure. Developing a new combined treatment strategy to overcome resistance to anti-PD-L1 and anti-VEGF is essential to improve patient outcomes. Stereotactic radiotherapy (SBRT) can enhance immune response through various mechanisms, and its immunomodulatory effect has been confirmed in multiple solid tumors. However, due to the limitation of the OAR tolerance dose, large-volume tumors are unsuitable for SBRT treatment. To overcome this issue, researchers have introduced the spatially fractionated radiation therapy (SFRT) mode, which allows for a highly uneven radiation dose distribution within the tumor volume. SFRT is an emerging radiotherapy technique with high clinical response rates and low radiation-related toxicity in large-volume solid tumors. Therefore, the investigators conducted this single-arm, single-arm, open-label study to evaluate the efficacy and safety of SFRT combined with PD-1 inhibitors and anti-VEGFR in unresectable HCC. The primary endpoint is objective response rate (ORR), and secondary endpoints include overall survival (OS), progression-free survival (PFS), and toxicity.",[136,137,28],"Hepatocellular Carcinoma","Radiotherapy",[136,139,28,140],"radiotherapy","SFRT","NOT_YET_RECRUITING","2024-11-25",{"date":144,"type":33},"2024-11-27",{"date":146,"type":20},"2025-01-01",{"date":95,"type":20},{"name":149,"class":40},"Guiping People's Hospital"]